NASDAQ · Biotechnology · USD
Context Therapeutics Inc. (CNTX) Stock Analysis
Context Therapeutics Inc. (CNTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CNTX Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.25
- Previous Close
- $0.24
- Day's Range
- 0.23–0.25
- 52-Week Range
- 0.22–3.62
- Volume
- 1.16M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.72
Valuation
- Market Cap
- $22.40M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −0.48
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$36.12M
- Shares Outstanding
- 91.88M
- 1-Year Return
- −81.78%
Dividend and dates
- Avg Volume
- 1.57M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CNTX closed at $0.23, −81.78% over 1 year.
Context Therapeutics Inc. (CNTX) has a market capitalization of $22.40M.
In fiscal 2025, CNTX reported revenue of $0.00.
CNTX Stock Return by Calendar Year
Context Therapeutics Inc. (CNTX) return since Oct 2021: what $10,000 became
- 1 year
- $10,000 $1,822
- −81.78%
- 5 years
- $10,000 $375
- −96.25%
- Since Oct 2021
- $10,000 $454
- −95.46%
If you had invested $10,000 in Context Therapeutics Inc. (CNTX) at the close on October 20, 2021, the earliest close on record here, it would have been worth $454 at the close on October 21, 2026: −95.46% in total, −46.11% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −84.26% |
| 2025 | +40.00% |
| 2024 | −7.08% |
| 2023 | +73.31% |
| 2022 | −75.49% |
| 2021 (partial year) | −47.84% |
As of October 21, 2026.
CNTX Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$36.12M | — |
| 2024 | $0.00 | −$26.73M | — |
| 2023 | $0.00 | −$23.96M | — |
| 2022 | $0.00 | −$14.84M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$39.70M | −$36.12M | — |
| 2024 | $0.00 | — | −$29.92M | −$26.73M | — |
| 2023 | $0.00 | — | −$25.07M | −$23.96M | — |
| 2022 | $0.00 | — | −$14.88M | −$14.84M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
YahooContext drops bispecific T-cell engager on cost-cutting initiative
pharmaceutical-technology.comEndometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More
YahooContext Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move
BenzingaContext Therapeutics Q2 EPS $(0.15) Misses $(0.09) Estimate
BenzingaContext Therapeutics Receives Nasdaq Noncompliance Notice, Gets Time Through Jan. 25 To Regain Compliance
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B